Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Neurology Rheumatology Diabetes / Metabolic Mental Health / Psychiatry Women's Health Dermatology Men's Health Rare Diseases
Clinical Trial ● Currently Recruiting NCT06314451

Cross-condition Validation of the Steroid PRO

Cross-condition Validation of the Steroid PRO — Recruiting • Respiratory / COPD / Asthma • NCT06314451.

📅 25 Mar 2026 ⏱ 1 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
NCT ID
NCT06314451
Sponsor
University of the West of England
Start
2022-06-01
ClinicaliQ Trial Snapshot
  • Cross-condition Validation of the Steroid PRO — Recruiting • Respiratory / COPD / Asthma • NCT06314451.
  • Testing a questionnaire about treatment with steroids for skin, lung or gastric conditions.
  • Sponsor: University of the West of England.

Verify eligibility, endpoints and current status on the original source registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

Testing a questionnaire about treatment with steroids for skin, lung or gastric conditions

Eligibility Snapshot
  • : * Aged ≥ 18 years old * Diagnosed with an autoimmune or inflammatory respiratory, gastroenterology or dermatology condition * Treatment with glucocorticoids with intravenous or oral glucocorticoids for an autoimmune or inflammatory condition within the previous year (or longer duration). * Ability to give consent.

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Digital technologies for applying algorithms to spirometry to support asthma and COPD diagnosis in primary care and community diagnostic centres: early-use assessment
Respiratory / COPD / Asthma · 02 Apr 2026
Digital spirometry algorithms can improve diagnostic accuracy for asthma and COPD in primary care and community diagnostic centres, potentially reducing unnecessary referrals…
View guideline →
Clinical Brief
‘My baby scratches and scratches’: Families say their homes are making their children sick
Respiratory / COPD / Asthma · BBC Health · 23 Apr 2026
Temporary housing conditions are contributing to increased rates of childhood skin conditions (notably atopic dermatitis), with families reporting persistent scratching and distress…
View brief →
Guideline
GINA 2024 Report: Global Strategy for Asthma Management and Prevention
Respiratory / COPD / Asthma · 31 Mar 2026
GINA 2024 reinforces no SABA-only treatment for any asthma severity: all patients should receive ICS-containing controller therapy or ICS-formoterol MART as first-line…
View guideline →
Clinical Brief
Asthma and COPD patients to receive better care closer to home
Respiratory / COPD / Asthma · NHS England · 17 Mar 2026
Asthma and chronic obstructive pulmonary disease (COPD) patients will receive better care closer to home under a landmark £10 million partnership. This…
View brief →
Clinical Brief
Could sleep app data help identify respiratory disease trends in England?
Respiratory / COPD / Asthma · UKHSA · 28 Jan 2026
UKHSA and Sleep Cycle are collaborating to analyse app-generated cough and sleep data to identify respiratory disease trends earlier across England's population…
View brief →
Clinical Brief
Short-acting beta 2 agonists (SABA) (salbutamol and terbutaline): reminder of the risks from overuse in asthma and to be aware of changes in the SABA prescribing guidelines
Respiratory / COPD / Asthma · MHRA · 24 Apr 2025
Healthcare professionals and patients are reminded of the risk of severe asthma attacks and increased mortality associated with overuse of SABA with…
View brief →